Yukimune Kanehira
Yukimune Kanehira is an expert in Pharmacy at Yamagata University Hospital (Japan). Yukimune Kanehira has authored 7 publications, the most recent in 2025. SLR score: 16 (community average: 125). How the SLR is computed.
LeadR Profile
Pharmacy
Subspecialties:
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2019 - 2026Yamagata University Hospital - Assistant professor
2025 - 2026
Number : 7
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Pirfenidone encapsulated in succinylated gelatin-coated liposomes exhibits sustained antifibrotic effects in vitro models of renal, pulmonary, and hepatic fibrosis. PMID 40345528 — fibrosis, pharmaceutical preparations, liposomes, collagen, pharmacy, enzymes, gelatin, matrix metalloproteinases, fibroblasts, therapeutics, retention, psychology, extracellular matrix, lip | J Pharm Sci | 2025 | 0 |
| Heterogenous Intrapulmonary Distribution of Aerosolized Model Compounds in Mice with Bleomycin-Induced Pulmonary Fibrosis. PMID 37843890 — idiopathic pulmonary fibrosis, bleomycin, administration, oral, lung, fibrosis, pharmaceutical preparations, imaging, three-dimensional, microscopy, pulmonary fibrosis, therapeutics, tissues, extracellular matrix | J Aerosol Med Pulm Drug Deliv | 2023 | 0 |
| Aerosolized Liposomal Formulation Prevents Enhanced Drug Transfer from Fibrotic Lungs to the Systemic Circulation. PMID 33372874 — solutions, plasma, epithelium, drug delivery systems, pharmaceutical preparations, cells, lung, idiopathic pulmonary fibrosis, tissues, indocyanine green, bleomycin | Curr Drug Deliv | 2020 | 0 |
| Intratumoral delivery and therapeutic efficacy of nanoparticle-encapsulated anti-tumor siRNA following intrapulmonary administration for potential treatment of lung cancer. PMID 31204552 — technology, pharmaceutical, drug delivery systems, pharmaceutical preparations, cells, therapeutics, lung neoplasms, nanoparticles, vascular endothelial growth factor a, rna, small interfering, interleukin-6, administration, intravenous | Pharm Dev Technol | 2019 | 9 |
| Efficient delivery to human lung fibroblasts (WI-38) of pirfenidone incorporated into liposomes modified with truncated basic fibroblast growth factor and its inhibitory effect on collagen synthesis in idiopathic pulmonary fibrosis. PMID 25747986 — cells, idiopathic pulmonary fibrosis, lung, growth, fibrosis, pharmaceutical preparations, liposomes, collagen, fibroblast growth factor 2, pulmonary fibrosis, pharmacology, hydroxyproline, toxicology, fibroblasts, fibroblast growth factors | Biol Pharm Bull | 2015 | 21 |
LeadR Networks
Main global connection map